Low antigen-dependent activity of T cells after repeated stimulation using dendritic cells and expansion with interleukin-2

Neoplasma

Volumn 50, Issue 5, 2003, Pages 345-349

  Buchler T ^a   Hajek R ^a   Kovarova L ^a   Musilova R ^a   Bourkova L ^a   Cech Z ^a   Vanova P ^a   Tuzova E ^a   Vidlakova P ^a   Vorlicek J ^a   Penka, M ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Dendritic cells; Immunotherapy; In vitro cell culture; T cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 7; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN DETECTION; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL CULTURE; CELL INTERACTION; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MONONUCLEAR CELL; NORMAL HUMAN; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR IMMUNOLOGY;

EID: 10744232358     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. BANCHEREAU J, STEINMAN RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
2. BECKER C, POHLA H, FRANKENBERGER B, SCHULER T, ASSENMACHER M, SCHENDEL DJ, BLANKENSTEIN T. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 2001; 7: 1159-1162.
3. BROSSART P, WIRTHS S, BRUGGER W, KANZ L. Dendritic cells in cancer vaccines. Exp Hematol 2001; 29: 1247-1255.
4. BÜCHLER T, HáJEK R. Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations. Med Oncol 2002; 19: 213-218.
5. GREENBERG PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49: 281-355.
6. GUINAN EC, GRIBBEN JG, BOUSSIONS VA, FREEMAN GJ, NADLER LM. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84: 3261-3282.
7. HAJEK R, BUTCH AW. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med Oncol 2000; 17: 2-15.
8. KIESSLING R, WASSERMAN K, HORIGUCHI S, KONO K, SJOBERG J, PISA P, PETERSSON M. Tumor-induced immune dysfunction. Cancer Immunol Immunother 1999; 48: 353-362.
9. KLARNET JP, KERN DE, OKUNO K, HOLT C, LILLY F, GREENBERG PD. FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens. J Exp Med 1989; 169:457-467.
10. KWAK LW, CAMPBELL MJ, CZERWINSKI DK, HART S, MILLER RA, LEVY R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 1209-1215.
11. MASSAIA M, BORRIONE P, BATTAGLIO S, MARIANI S, BEGGIATO E, NAPOLI P, VOENA C, BIANCHI A, COSCIA M, BESOSTRI B, PEOLA S, STIEFEL T, EVEN J, NOVERO D, BOCCADORO M, PILERI A. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999; 94: 673-683.
12. MERAD M, SUGIE T, ENGLEMAN EG, FONG L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 2002; 99: 1676-1682.
13. MOORE KW, O'GARA A, DE WAAL MALEFYT R, VIEIRA P, MOSMANN TR. Interleukin-10. Annu Rev Immunol 1993; 11: 165-190.
14. MOSCA PJ, HOBEIKA AC, CLAY TM, NAIR SK, THOMAS EK, MORSE MA, LYERLY HK. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood 2000; 96: 3499-3504.
15. MUTIS T, VERDIJK R, SCHRAMA E, ESENDAM B. BRAND A, GOULMY E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93: 2336-2341.
16. OSSENDORP F, MENGEDE E, CAMPS M, FILIUS R, MELIEF CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 1998; 187: 693-702.
17. ROMANI N, REIDER D, HEUER M, EBNER S, KAMPGEN E, EIBL B, NIEDERWIESER D, SCHULER G. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996; 196: 137-151.
18. SCHULTZE JL, MAECKER B, VON BERGWELT-BAILDON MS, ANDERSON KS, VONDERHEIDE RH. Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens. Vox Saguinis 2001; 80: 81-89.
19. SCHULTZE JL. Why do B cell lymphona fail to elicit clinically sufficient T cell immune responses? Leuk Lymphoma 1999; 32: 223-236.
20. SCHWARTZ JC, ZHANG X, NATHENSON SG, ALMO SC. Structural mechanisms of costimulation. Nat Immunol 2002; 3: 427-434.
21. SCHWARTZ RH. A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349-1356.
22. WEN YJ, BARLOGIE B, YI Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood 2001; 97: 1750-1755.
23. ZHU M, TERASAWA H, GULLEY J, PANICALI D, ARLEN P, SCHLOM J, TSANG KY. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res 2001; 61: 3725-3734.